Literature DB >> 29614499

MicroRNA-330-3p Expression Indicates Good Prognosis and Suppresses Cell Proliferation by Targeting Bmi-1 in Osteosarcoma.

Zhenxin Zheng1, Feng Bao1, Xuhong Chen1, Hongbin Huang1, Xiangfeng Zhang2.   

Abstract

BACKGROUND/AIMS: Growing evidence has shown that miR-330-3p is closely related to the biological behavior of cancer, including proliferation, metastasis, and prognosis. However, there have been no reports on miR-330-3p expression and function in osteosarcoma.
METHODS: Expression of miR-330-3p in osteosarcoma tissues and cell lines was examined by quantitative PCR. Effects of miR-330-3p on osteosarcoma cell proliferation were investigated in vitro with the Cell Counting Kit-8 colorimetric assay. Targets of miR-330-3p were identified by dual-luciferase reporter assay.
RESULTS: The results showed that expression of miR-330 decreased in osteosarcoma tissues and cell lines. Prognosis of patients with high miR-330-3p expression was much better than that of those with low expression (P=0.001), and multivariate analysis suggested that miR-330-3p is an independent prognostic factor for osteosarcoma. In addition, miR-330-3p overexpression significantly inhibited the growth of MG-63 and U2OS osteosarcoma cells. Dual-luciferase reporter assay demonstrated that Bmi-1 was a direct target gene of miR-330-3p, and in a recovery experiment, miR-330-3p suppressed osteosarcoma cell proliferation by directly targeting Bmi-1.
CONCLUSION: Our results suggest that miR-330-3p acts as a tumor suppressor by regulating Bmi-1 expression in osteosarcoma. Thus, miR-330-3p may represent a novel therapeutic target for the treatment of osteosarcoma.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Bmi-1; MicroRNA-330-3p; Osteosarcoma; Tumor suppressor

Mesh:

Substances:

Year:  2018        PMID: 29614499     DOI: 10.1159/000488612

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  7 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  The homeostatic malfunction of a novel feedback pathway formed by lncRNA021545, miR-330-3p and epiregulin contributes in hepatocarcinoma progression via mediating epithelial-mesenchymal transition.

Authors:  Siwen Yang; Yunkun Zhang; Chunmei Guo; Rui Liu; Maroua Elkharti; Zhenhua Ge; Qinlong Liu; Shuqing Liu; Ming-Zhong Sun
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

3.  BMI‑1 promotes invasion and metastasis in endometrial adenocarcinoma and is a poor prognostic factor.

Authors:  Jing Yu; Ling Chen; Zhenhua Bao; Ying Liu; Guohong Liu; Fengling Li; Lianqin Li
Journal:  Oncol Rep       Date:  2020-03-10       Impact factor: 3.906

4.  Hsa_circ_0032463 acts as the tumor promoter in osteosarcoma by regulating the miR‑330‑3p/PNN axis.

Authors:  Guanghua Qin; Xuejian Wu
Journal:  Int J Mol Med       Date:  2021-03-31       Impact factor: 4.101

5.  Correlation between Patient-Derived Xenograft Modeling and Prognosis in Osteosarcoma.

Authors:  Mengxiong Sun; Zongyi Wang; Wei Sun; Ming Chen; Xiaojun Ma; Jiakang Shen; Zeze Fu; Dongqing Zuo; Gangyang Wang; Hongsheng Wang; Chongren Wang; Fei Yin; Zhuoying Wang; Chuanying Zhang; Yingqi Hua; Zhengdong Cai
Journal:  Orthop Surg       Date:  2022-05-10       Impact factor: 2.279

6.  Accumulation of kynurenine elevates oxidative stress and alters microRNA profile in human bone marrow stromal cells.

Authors:  Sherwood Dalton; Kathryn Smith; Kanwar Singh; Helen Kaiser; Ravindra Kolhe; Ashis K Mondal; Andrew Khayrullin; Carlos M Isales; Mark W Hamrick; William D Hill; Sadanand Fulzele
Journal:  Exp Gerontol       Date:  2019-11-30       Impact factor: 4.032

7.  Deduction of novel genes potentially involved in hypoxic AC16 human cardiomyocytes using next-generation sequencing and bioinformatics approaches.

Authors:  Wen-Hsien Lee; Ming-Ju Tsai; Wei-An Chang; Ling-Yu Wu; Han-Ying Wang; Kuo-Feng Chang; Ho-Ming Su; Po-Lin Kuo
Journal:  Int J Mol Med       Date:  2018-08-31       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.